Abstract

: To compare the efficacy of mitomycin C (MMC) and Ologen implant (OLO) as adjuvants in Trabeculectomy in patients with POAG in eastern India.: It was a hospital based prospective randomized parallel group comparative study from November 2019 to April 2021. Forty eyes of forty patients of POAG with inadequate intraocular pressure (IOP) control were enrolled and randomly divided them into two groups of twenty. Group A (MMC) patients underwent MMC trabeculectomy, while Group B (OLO) patients underwent OLO trabeculectomy. All the cases were followed up post-operatively for six months, and the recorded IOP of each visit was analyses using software R 4.0.3 and R-studio.: The preoperative IOP for the OLO group was 34.0 mmHg (IQR: 30.75 – 38.0), while for the MMC intervention group it was 36.50 mmHg (IQR: 31- 42). The difference in IOP between the two groups was insignificant (p= 0.24). On the first postoperative day, the IOP in the MMC group was 10.05 ± 3.65 mmHg and in the OLO group it was 10.35 ± 2.13 mmHg. Seven days after surgery, the mean IOP in MMC group was 9.45 ± 3.0 mmHg, while it was 11.50 ± 2.52 mmHg in the OLO group. One month after surgery, the mean IOP in the MMC group was 11.15 ± 4.25 mmHg, whereas it was 11.50±5.02 mmHg in OLO group. At 3 months postoperatively, the mean IOP in the MMC group was 12.25± 5.17 mmHg, while it was 12.70± 1.84 mmHg in the OLO group. Six months after surgery, the mean IOP in the MMC group was 10.50± 2.72 mmHg, whereas in the OLO group it was 13.35± 2.94 mmHg. In both the groups, there was significant reduction of IOP (p value < 0.05) observed in all postoperative visits.: In trabeculectomy surgery on POAG eyes, the MMC and OLO implants both successfully lower IOP. Between the two groups, there was no statistically significant difference in the success rate.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.